Loading this company
UnitedHealth Group Incorporated
UNHPrices in USD
TickerWorth ScoreC55/100
What we think
Priced within our range of $401.25 to $544.32.A range by design: peer multiples and our researched mid-cycle DCF.
Price
$407.40USD up +$5.95 (+1.48%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 2 models, on today’s numbers
$401.25–$544.32
A range by design: peer multiples and our researched mid-cycle DCF.
What the price needs: revenue growth of 0.7%/yr for 5 years (our model assumes 3.4%).
Led by peer multiples (P/E, EV/EBITDA, P/S) · Cyclical business
Price $407.40Priced · Prices are delayed.
Is it a good business?
- Valuation50 out of 100
- Growth67 out of 100
- Financial health33 out of 100
- Dividend100 out of 100
- Past performance83 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$477.04 across 25 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
UnitedHealth Group Incorporated operates as a health care company in the United States and internationally. It operates through four segments: Optum Health, Optum Insight, Optum Rx; and UnitedHealthcare. It operates in the Healthcare Plans industry (Healthcare sector), headquartered in United States. The company employs roughly 390,000 people.
Key stats
52-week range$255.97–$461.62
- Open
- $399.69
- Day high
- $407.84
- Day low
- $399.20
- Previous close
- $401.45
- Volume
- 524,212 · 0.10× avg
- Average volume
- 5,068,876
- Market cap
- $365,680,132,096.00
- P/E (TTM)
- 26.20
- Earnings per share
- $15.55
- Beta
- 0.62
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Reported quarterly or annual results
- Issued a public disclosure (Reg FD)
- Reported quarterly or annual results
- Reported shareholder vote results
- Issued a public disclosure (Reg FD)
- Reported quarterly or annual results
- Issued a public disclosure (Reg FD)
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Noseworthy John HGrant / award · —
- MONTGOMERY RICE VALERIE MDGrant / award · —
- MCNABB FREDERICK WILLIAM III
Not investment advice. TickerWorth Score is a model output.